Modality
Multispecific
MOA
CFTRmod
Target
WEE1
Pathway
Proteasome
Gastric CaMCCNarcolepsy
Development Pipeline
Preclinical
~Sep 2010
→ ~Dec 2011
Phase 1
~Mar 2012
→ ~Jun 2013
Phase 2
~Sep 2013
→ ~Dec 2014
Phase 3
~Mar 2015
→ ~Jun 2016
NDA/BLA
~Sep 2016
→ ~Dec 2017
Approved
Mar 2018
→ Jan 2030
ApprovedCurrent
NCT04500954
437 pts·MCC
2022-11→2029-05·Terminated
NCT07208165
2,009 pts·Narcolepsy
2018-03→2030-01·Terminated
2,446 total pts2 indications
CompletedCurrentUpcoming
Catalysts (2)
2029-05-263.2y awayPh3 Readout· MCC
2030-01-083.8y awayPh3 Readout· Narcolepsy
Trial Timeline
2018Q2Q3Q42019Q2Q3Q42020Q2Q3Q42021Q2Q3Q42022Q2Q3Q42023Q2Q3Q42024Q2Q3Q42025Q2Q3Q42026Q2Q3Q42027Q2Q3Q42028Q2Q3Q42029Q2Q3Q42030Q2
Approved
Termina…
Approved
Termina…
Catalysts
Ph3 Readout
2029-05-26 · 3.2y away
MCC
Ph3 Readout
2030-01-08 · 3.8y away
Narcolepsy
Terminated|StartCompletionToday
Trials (2)
| NCT | Phase | Indication | Status | N | EP |
|---|---|---|---|---|---|
| NCT04500954 | Approved | MCC | Terminated | 437 | PASI75 |
| NCT07208165 | Approved | Narcolepsy | Terminated | 2009 | DOR |
Competitors (10)
| Drug | Company | Phase | Target | MOA |
|---|---|---|---|---|
| LLY-4358 | Eli Lilly | Phase 3 | B7-H3 | |
| Gelinaritide | AbbVie | Preclinical | FcRn | |
| TAK-2403 | Takeda | Phase 2 | WEE1 | |
| Sovacapivasertib | Amgen | Phase 3 | WEE1 | |
| Darafutibatinib | BioNTech | Preclinical | PRMT5 | |
| ALN-8757 | Alnylam | Preclinical | TIGIT | |
| Fixaglumide | Genmab | Phase 2/3 | WEE1 | |
| Sovarasimod | Halozyme | Phase 1/2 | WEE1 | |
| Ivotuximab | Madrigal Pharma | Phase 2 | CD123 | |
| Bemavorutinib | Acadia Pharma | Phase 1/2 | WEE1 |